Importantly, the Sacklers are not shielded from potential criminal charges under this settlement, leaving the possibility for future legal actions if new evidence emerges.

Families impacted by the opioid epidemic, like Teri Kroll, have expressed that no amount of money can replace their lost loved ones, emphasizing the need for accountability and support.

Purdue Pharma and the Sackler family have reached a significant agreement to pay up to $7.4 billion to settle lawsuits related to the opioid crisis, marking a pivotal moment in the ongoing battle against addiction.

New York Attorney General Letitia James described the settlement as a form of justice for victims harmed by the Sacklers' prioritization of profit over people.

In 2023, law enforcement seized over 115 million illegal fentanyl pills, highlighting the ongoing crisis, which has resulted in hundreds of thousands of deaths in the U.S. since the release of OxyContin in 1996.

The opioid crisis has been exacerbated by the overprescription of OxyContin, which Purdue Pharma manufactured, and has led to a staggering number of opioid-related deaths, particularly due to illicit fentanyl.

Attorney General William Tong emphasized that this settlement holds the Sackler family accountable, although it may not significantly impact their wealth, and reflects the broader fight for justice in the wake of the opioid epidemic.

The settlement funds are earmarked for programs aimed at combating addiction and supporting detoxification efforts, with a focus on treatment, prevention, and recovery over the next 15 years.

While the settlement is a major step forward, it still requires court approval, and some details remain unresolved, although federal opposition is not anticipated under the current administration.

Critics of previous bankruptcy plans argued that the Sacklers were not held accountable enough, while supporters believed that these plans would provide essential funding for communities affected by the opioid crisis.

As part of the agreement, the Sackler family will relinquish control over Purdue Pharma and its ability to sell opioids in the U.S., a move that aims to enhance accountability.

The agreement includes a provision for an initial set-aside of $200 million, which could increase to $800 million for defending against future claims, with any unused funds reverting to states after five years.